{"nctId":"NCT00119106","briefTitle":"Bangkok Tenofovir Study, an HIV Pre-exposure Prophylaxis Trial, Bangkok, Thailand","startDateStruct":{"date":"2005-06"},"conditions":["HIV Infections"],"count":2413,"armGroups":[{"label":"tenofovir disoproxil fumarate","type":"EXPERIMENTAL","interventionNames":["Drug: Tenofovir disoproxil"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tenofovir disoproxil","otherNames":["Tenofovir"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Report injection drug use in the 6 months before screening\n* Possess a Thai National Identification Card\n* Laboratory values as follows within 2 weeks before enrollment:\n* HIV oral fluid test non-reactive at screening and pre-enrollment visits\n* Hemoglobin 9 gm/dL\n* ALT and AST 2.5 x upper limit of normal (ULN)\n* Total bilirubin 1.5 mg/dL\n* Serum amylase 1.5 x ULN\n* Serum phosphorus 2.2 mg/dL\n* No evidence of current or chronic Hepatitis B infection by serology\n* Calculated creatinine clearance 60 mL/min by the Cockcroft-Gault formula where creatinine clearance in mL/min = Male: (140 - age in years) x (wt in kg)/72 x (serum creatinine in mg/dL) Female:(140 - age in years) x (wt in kg) x 0.85/72 x (serum creatinine in mg/dL)\n* Willing to abstain from sexual intercourse or use effective contraception during the trial (oral, injection, or barrier), for women\n* Willing and able to provide informed consent for study participation\n* Available and committed to DOT or monthly follow-up for at least 12 months\n\nExclusion Criteria:\n\n* Clinic physicians will determine if a subject with chronic illness requiring prescription medication can not enroll (medication used for drug treatment is allowed)\n* Positive urine pregnancy test\n* Breastfeeding\n* History of significant renal, liver, or bone disease\n* Any other clinical condition or prior therapy that, in the opinion of the clinic physician, would make the subject unsuitable for the study or unable to comply with the dosing requirements\n* Concurrent participation in any other HIV prevention trial or drug/vaccine safety trial. AIDSVAX B/E HIV vaccine trial (CDC protocol #2076) participants and Extension Study (CDC protocol #3750) participants may be screened for enrollment in the Bangkok Tenofovir Study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"20 Years","maximumAge":"60 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Rates of HIV Seroconversion","description":"Kaplan Meier survival curve.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Renal Toxicity","description":"Number of Participants with Grade 3 or 4 Renal Laboratory Toxicities","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"PRIMARY","title":"Adverse Events","description":"Number of Participants with adverse clinical events in tenofovir and placebo arms","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1098","spread":null},{"groupId":"OG001","value":"1083","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Injecting and Sharing Needles","description":"Number of Participants reporting injecting and sharing needles:\n\nAssessed injecting and sharing at baseline and every 3 months during follow-up. We used GEE to determine if there was a significant decline in injecting and sharing.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Adherence to Study Drug/Placebo","description":"Mean number of days that participants took study drug based on study drug diaries by study group.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":"23"},{"groupId":"OG001","value":"84","spread":"23"}]}]}]},{"type":"SECONDARY","title":"HIV Viral Load Copies/mL Measured at First Positive HIV Test Result by Group","description":"Plasma HIV RNA concentrations.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"929829","spread":"2272690"},{"groupId":"OG001","value":"120061","spread":"222612"}]}]}]},{"type":"SECONDARY","title":"Number Participants Who Reported More Than One Sexual Partner at Baseline","description":"Number of participants","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Tenofovir-associated Resistance Mutations.","description":"Measure tenofovir associated resistance mutations (ie, K65R and K70E) in amplified viral RNA specimens from HIV-positive participants in the placebo and tenofovir groups.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":227,"n":1204},"commonTop":["AE","Renal toxicity"]}}}